Following a 2-month delay, the Facilities for Illness Management and Prevention (CDC) vaccine advisory committee, after conferences this week, made suggestions for 3 vaccines.
After discussions on a number of vaccines yesterday and immediately, the Advisory Committee for Immunization Practices (ACIP) immediately voted on suggestions for GSK’s pentavalent (five-strain) meningococcal vaccine, respiratory syncytial vaccine (RSV) use in individuals ages 50 to 59 years outdated who’re at elevated danger for extreme illness, and Bavarian Nordic’s newly authorised vaccine-like particle chikungunya vaccine.
Advisable use for brand spanking new meningococcal vaccine
For meningococcal vaccines, ACIP beneficial that GSK’s pentavalent vaccine (Penmenvy), designed to guard towards A, B, C, W, and Y serogroups and authorised in February, be used when the quadrivalent (four-strain) and meningitis B vaccine are indicated on the identical go to.
The advice applies to wholesome individuals ages 16 to 23 years outdated on a routine vaccine schedule when shared medical decision-making favors meningitis B vaccination. It additionally applies to individuals ages 10 years and older who’re at elevated danger of meningococcal illness.
The vote, and a companion vote on recommending the vaccine for the Vaccines for Youngsters (VFC) program, which supplies free doses for eligible youngsters, handed unanimously.
RSV vaccine for bigger group of at-risk adults
Within the RSV vaccine vote, ACIP beneficial that that adults ages 50 to 59 who’re at elevated danger of extreme illness obtain a single dose. The vaccine was beforehand beneficial for all adults ages 75 and older and for these ages 60 to 74 years outdated who’re at elevated danger of extreme illness.
In recommending the vaccine for danger teams within the youthful grownup group, the CDC stated it might publish medical issues that spell out the persistent situations and different danger components for extreme illness that underpin its recommendation.
The vote handed 14 to 0, with 1 abstention.
After the vote, a number of ACIP members urged researchers and the vaccine corporations to gather extra info on period of safety for additional readability. The comparatively new vaccine is at the moment beneficial as a single dose for all beneficial grownup age-groups.
Security sign for Valneva vaccine affected chikungunya dialogue
The advisers additionally beneficial Bavarian Nordic’s newly authorised chikungunya vaccine (Vimkunya) for adults who’re touring to a rustic or a territory experiencing an outbreak. Additionally they stated the vaccine could also be thought of for adults earlier than touring or shifting to a rustic or territory with out an outbreak however at an elevated danger for a interval of 6 months or longer.
In a separate vote, the group additionally beneficial the vaccine for lab staff who’re doubtlessly uncovered to the chikungunya virus.
At the moment’s votes additionally mirrored discussions over a possible security sign for Valneva’s live-attenuated chikungunya in adults ages 65 years and older. In early March, the CDC stated it was investigating 5 hospitalizations for cardiac and neurologic occasions in individuals ages 65 and older who had acquired Valneva’s Ixchiq vaccine, which acquired Meals and Drug Administration (FDA) approval in November 2023.
With two chikungunya vaccines available on the market, the ACIP made related suggestions for each, aside from the age suggestions, and added wording noting that being age 65 and older is a precaution for the live-attenuated Valneva vaccine.
The three chikungunya vaccine votes handed 14 to 0, with 1 abstention.
The CDC will think about the ACIP suggestions earlier than making a ultimate determination. The company, nevertheless, normally adopts ACIP’s recommendation.
